Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00833170

Recruitment Status : Active, not recruiting

First Posted : January 30, 2009

Last Update Posted : January 26, 2018

Sponsor:

Collaborator:

Centocor, Inc.

Information provided by (Responsible Party):

Jeffrey Hyams, MD, Connecticut Children's Medical Center

Study Description

Brief Summary:

The purpose of the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry is to study the contemporary natural history of children <16 years of age newly diagnosed with inflammatory bowel disease. The project follows these children quarterly from diagnosis examining clinical, laboratory, and humanistic outcomes. Genetic and serologic monitoring is performed on the study population.

Condition or disease
Inflammatory Bowel Disease

Detailed Description:

Observations of children with IBD often suggest a more severe course than that found in adults. Explanations for this are unclear, especially since children are less likely to engage in some behaviors (e.g., smoking) that may have a deleterious effect on disease course as noted in adults. In many ways children are a better "experimental model" of IBD because they don't have as many confounding medical factors as adults. Both Crohn's disease and ulcerative colitis are believed to result from a complex interaction of genetic and environmental factors (1). Recently, the gene CARD15/NOD2 on chromosome 16 has been identified in approximately 25% of Caucasian patients with Crohn's disease and is felt to be a significant predisposing factor to the development of fibrostenosing disease (2). Additionally, seropositivity for perinuclear antinuclear cytoplasmic factor (pANCA) has been demonstrated much more frequently in patients with ulcerative colitis than in those with Crohn's disease, while anti-Saccharomyces antibody (ASCA) is more common in the latter population (3). The importance of these serological abnormalities is not clear, though some data suggest an influence on the development of complications.

Our hypothesis is that phenotypic, genotypic and serologic characteristics may provide prognostic information on response to therapy and course in children with IBD. This type of prognostic information is particularly important as newer therapies are developed.

Study Design


Study Type :	Observational
Estimated Enrollment :	1000 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry
Actual Study Start Date :	January 28, 2002
Estimated Primary Completion Date :	August 2019
Estimated Study Completion Date :	August 2019

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

Clinical activity following biologic and immunomodulatory therapy [ Time Frame: 10 years ]
Clinical Outcomes

Biospecimen Retention: Samples With DNA

Blood

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	1 Month to 16 Years (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Children <16 years old with inflammatory bowel disease

Criteria

Inclusion Criteria:

Definite diagnosis of ulcerative colitis, Crohn's disease, indeterminate colitis
Age up to 16 years and zero days at time of diagnosis
Informed consent/assent from parent/guardian and patient
Ability to be available for regular follow-up visits

Exclusion Criteria:

Diagnosis of IBD greater than 1 month prior to presentation to participating center
Age greater than 16 years and zero days
Inability to be available for regular follow-up visits

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00833170

Show 28 Study Locations

Sponsors and Collaborators

Connecticut Children's Medical Center

Centocor, Inc.

Investigators


Principal Investigator:	Jeffrey S. Hyams, M.D.	Connecticut Children's Medical Center

More Information


Responsible Party:	Jeffrey Hyams, MD, Study Principal Investigator, Connecticut Children's Medical Center
ClinicalTrials.gov Identifier:	NCT00833170 History of Changes
Other Study ID Numbers:	PIBDCRG1
First Posted:	January 30, 2009 Key Record Dates
Last Update Posted:	January 26, 2018
Last Verified:	January 2018

Keywords provided by Jeffrey Hyams, MD, Connecticut Children's Medical Center:


pediatric inflammatory bowel disease multiple site study

Additional relevant MeSH terms:


Intestinal Diseases Inflammatory Bowel Diseases Gastrointestinal Diseases Digestive System Diseases Gastroenteritis

To Top